FDA ApprovedUnited States
Weekly Treatment for Children with Achondroplasia
Yuviwel (navepegritide) — once-weekly CNP analog for children ≥2 with achondroplasia
FDA accelerated approval on 27 February 2026 for Yuviwel (navepegritide) for injection — a C-type natriuretic peptide (CNP) analog / TransCon CNP prodrug — to…
This is for families of children aged 2 years and older with achondroplasia and open growth plates who may be candidates for a labelled US once-weekly…